VaishaliSanchorawalaMD

Hematology • Boston, MA

Professor, Medicine, Boston University School of Medicine

Join to view full profile

Dr. Sanchorawala is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sanchorawala's full profile

Already have an account?

Office
830 Harrison Ave 3rd FL
Moakley Hematologyoncology
Boston, MA 02118
Phone+1 617-638-6428

Fax+1 617-638-5756

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1997
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1991 - 1994
Seth G.S. Medical CollegeClass of 1990

Certifications & Licensure

MA State Medical License 1994 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis Start of enrollment: 2004 Jan 01
Completed
Phase 2
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis Start of enrollment: 2000 Aug 01
Completed
Phase 2
HD Melphalan and SCT in Patients With IGDD or LCDD Start of enrollment: 2006 Oct 01
Terminated
Phase 2
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 2008 Jun 01
Completed
Phase 2
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Start of enrollment: 2009 Sep 01
Completed
Phase 2
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Scleroderma Treatment With Autologous Transplant (STAT) Study Start of enrollment: 2011 Sep 15
Active, not recruiting
Phase 2
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis Start of enrollment: 2012 Jun 01
Completed
Phase 1, Phase 2
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Start of enrollment: 2013 Mar 01
Terminated
Phase 1
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
Daratumumab for the Treatment of Patients With AL Amyloidosis Start of enrollment: 2017 Mar 20
Completed
Phase 1, Phase 2
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis Start of enrollment: 2020 Aug 06
Terminated
Phase 1
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab Start of enrollment: 2021 Apr 14
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Collection of Samples and Clinical Data From Patients With Amyloid Diseases Start of enrollment: 2000 Jan 01
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

55 citations
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis.
Giovanni Palladini, Stefan Schönland, Vaishali Sanchorawala, Shaji Kumar, Ashutosh D. Wechalekar
Amyloid. 2021-01-07
24 citations
Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis.
Amanda Schulman, Lawreen H. Connors, Janice Weinberg, Lisa M Mendelson, Tracy Joshi
European Journal of Haematology. 2020-07-20
293 citations
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
Raymond L. Comenzo, Donna E. Reece, Giovanni Palladini, David C. Seldin, Vaishali Sanchorawala
Leukemia. 2012-11-01

Journal Articles

Development and Validation of a Survival Staging System Incorporating BNP in Patients with Light Chain (AL) Amyloidosis
Frederick L Ruberg, Vaishali Sanchorawala, Blood
Heparin-Induced Thrombocytopenia and Thrombosis During High Dose Melphalan and Autologous Stem Cell Transplantation
Dina Brauneis, Vaishali Sanchorawala, J Mark Sloan, Shayna Sarosiek, Blood

Abstracts/Posters

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
Vaishali Sanchorawala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus PhysicianÍs Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary...
Vaishali Sanchorawala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results o...
Vaishali Sanchorawala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact
Vaishali Sanchorawala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study
Vaishali Sanchorawala, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Untangling Amyloidosis 2019
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Vaishali Sanchorawala: Her Pioneering Research into the Rare Disease Amyloidosis Defines the FieldFebruary 24th, 2021
Organ Responses After Highdose Melphalan and Stemcell Transplantation in AL AmyloidosisJuly 31st, 2020
Anti-Cancer Drug Safe and Effective for Treating Light Chain (AL) AmyloidosisFebruary 3rd, 2020
Join now to see all